Published in Curr Opin Cardiol on November 01, 2010
ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity. J Biomed Res (2011) 0.83
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation (2006) 6.17
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet (2010) 5.31
Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 4.08
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol (2012) 3.66
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. Circulation (2007) 3.20
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation (2011) 3.01
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol (2008) 2.51
Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med (2008) 2.30
Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation (2008) 2.30
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.29
Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med (2007) 2.26
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.22
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Red cell distribution width is associated with physical inactivity and heart failure, independent of established risk factors, inflammation or iron metabolism; the EPIC-Norfolk study. Int J Cardiol (2013) 2.05
High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med (2009) 2.02
Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart (2010) 1.91
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation (2012) 1.76
Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation (2010) 1.75
Serum levels of mannose-binding lectin and the risk of future coronary artery disease in apparently healthy men and women. Arterioscler Thromb Vasc Biol (2006) 1.62
The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study. CMAJ (2010) 1.45
Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol (2011) 1.43
Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study. Eur Heart J (2013) 1.41
C-reactive protein is a mediator of cardiovascular disease. Eur Heart J (2010) 1.38
ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. Arterioscler Thromb Vasc Biol (2008) 1.34
Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol (2007) 1.34
Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol (2010) 1.34
Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. Eur Heart J (2009) 1.31
Inherited disorders of HDL metabolism and atherosclerosis. Curr Opin Lipidol (2005) 1.29
Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J Lipid Res (2006) 1.28
Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. Circulation (2007) 1.23
HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis (2009) 1.21
Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. Circulation (2009) 1.20
PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circulation (2010) 1.14
Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation (2002) 1.13
The role of non-HDL cholesterol in risk stratification for coronary artery disease. Curr Atheroscler Rep (2012) 1.11
Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. J Clin Endocrinol Metab (2008) 1.10
Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res (2011) 1.09
Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol (2005) 1.08
Gene polymorphisms and the risk of myocardial infarction--an emerging relation. N Engl J Med (2002) 1.07
Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol (2012) 1.04
Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. Eur Heart J (2007) 1.04
Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study. J Lipid Res (2006) 1.03
Retracted Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol (2012) 1.01
The relationship between plasma angiopoietin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk. Arterioscler Thromb Vasc Biol (2010) 1.00
Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. Arterioscler Thromb Vasc Biol (2009) 0.97
Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol (2006) 0.94
Polymorphisms in APOA1 and LPL genes are statistically independently associated with fasting TG in men with CAD. Eur J Hum Genet (2005) 0.93
Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. PLoS One (2009) 0.93
Physical activity, the Framingham risk score and risk of coronary heart disease in men and women of the EPIC-Norfolk study. Atherosclerosis (2009) 0.92
Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. Atherosclerosis (2010) 0.90
C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-Norfolk cohort study. Arterioscler Thromb Vasc Biol (2013) 0.89
Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Int J Cardiol (2009) 0.87
Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size. Clin Chem (2010) 0.86
Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. Eur J Hum Genet (2005) 0.86
Physical activity, metabolic syndrome, and coronary risk: the EPIC-Norfolk prospective population study. Eur J Cardiovasc Prev Rehabil (2011) 0.86
Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study). Am J Cardiol (2011) 0.86
Lipid assessment, metabolic syndrome and coronary heart disease risk. Eur J Clin Invest (2010) 0.85
Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier? Circulation (2008) 0.84
The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ Cardiovasc Genet (2011) 0.84
Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study. Eur J Clin Invest (2013) 0.84
Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease. Arterioscler Thromb Vasc Biol (2010) 0.83
Major depression, C-reactive protein, and incident ischemic heart disease in healthy men and women. Psychosom Med (2008) 0.83
Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ Cardiovasc Genet (2009) 0.82
Varespladib: targeting the inflammatory face of atherosclerosis. Eur Heart J (2010) 0.80
Incremental diagnostic accuracy of hybrid SPECT/CT coronary angiography in a population with an intermediate to high pre-test likelihood of coronary artery disease. Eur Heart J Cardiovasc Imaging (2013) 0.80
A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort. Eur J Prev Cardiol (2012) 0.79
High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation (2013) 0.79
High-sensitivity troponin T is associated with poor outcome in adults with pulmonary arterial hypertension due to congenital heart disease. Congenit Heart Dis (2012) 0.79
Relationship between atorvastatin dose and the harm caused by torcetrapib. J Lipid Res (2012) 0.79
Thrombospondin gene polymorphisms and the risk of angiographic coronary in-stent restenosis. Am J Med (2004) 0.78
Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention. Pharmacogenet Genomics (2010) 0.78
Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels. Circ Cardiovasc Genet (2014) 0.78
Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. Curr Opin Lipidol (2015) 0.78
Usefulness of coronary calcium scoring to myocardial perfusion SPECT in the diagnosis of coronary artery disease in a predominantly high risk population. Int J Cardiovasc Imaging (2012) 0.77
Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis, and toll-like receptor 4 gene polymorphisms. Clin Chem (2005) 0.76
De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough? Eur Heart J (2011) 0.76
Dilation of the Aorta Ascendens Forms Part of the Clinical Spectrum of HCN4 Mutations. J Am Coll Cardiol (2016) 0.75
The authors’ reply. Heart (2013) 0.75
Reply: statin-induced low low-density lipoprotein cholesterol level: is lower better? J Am Coll Cardiol (2015) 0.75
Response to letter by Balta et al. Int J Cardiol (2013) 0.75
Improving risk stratification for cardiovascular disease. Expert Rev Cardiovasc Ther (2010) 0.75
Reply: To PMID 23219296. J Am Coll Cardiol (2013) 0.75
Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease. Int J Mol Epidemiol Genet (2011) 0.75
Rates and determinants of progressive aortic valve dysfunction in aortic coarctation. Int J Cardiol (2012) 0.75
IgM antibodies against apoptotic cells and phosphorylcholine in patients with acute myocardial infarction in relation to infarct size and inflammatory response. Adv Clin Exp Med (2012) 0.75
Clinical and biological relevance of statin-mediated changes in HDL metabolism. Curr Atheroscler Rep (2014) 0.75
Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms. J Am Coll Cardiol (2017) 0.75
Coronary Artery Disease Affects Symptomatology of Aortic Valve Stenosis. J Am Coll Cardiol (2017) 0.75
Impact of abdominal obesity and systemic hypertension on risk of coronary heart disease in men and women: the EPIC-Norfolk Population Study. J Hypertens (2014) 0.75